Praxgen Pharmaceuticals
  • Home
  • Business Development
  • News
  • Careers
  • Contact Us
Praxgen Pharmaceuticals

Practical, Accessible Generics

Practical, Accessible GenericsPractical, Accessible GenericsPractical, Accessible Generics

Sensible solutions. Forward thinking.

Contact Us

6096061032

  • Home
  • Business Development
  • News
  • Careers
  • Contact Us

What We Do

Commitment to Health

Drug Development and Testing

Drug Development and Testing

Our company aims to create a healthier future for patients while increasing shareholder value through the development and introduction of quality, affordable generic products by experienced, passionate and talented pharmaceutical professionals. 

Drug Development and Testing

Drug Development and Testing

Drug Development and Testing

Praxgen is a specialty pharmaceutical company focused on development, manufacturing and marketing of high-quality generic prescription pharmaceuticals that improve patient health while creating stakeholder value. We specialize in difficult-to-manufacture and complex dosage forms, including ophthalmics, injectables, topicals and oral solids. 

Pharmaceutical Manufacturing

Drug Development and Testing

Pharmaceutical Manufacturing

We have Research and Development facilities in Princeton, NJ and Monmouth Junction, NJ, and several manufacturing facilities across North America and Asia through partnerships and contract manufacturing. 

About Us

Portfolio

Arthur Pharma

Portfolio

Praxgen has over 40 products under development at various stages that have been and will be filed with the FDA and Chinese FDA.

Find out more

About Us

Arthur Pharma

Portfolio

Praxgen Pharmaceuticals, formerly SunGen Pharma, was founded in 2016 by a team of distinguished pharma executives. The name Praxgen reflects our commitment to a practical and accessible path to patient health through high-quality generic pharmaceuticals. 

Arthur Pharma

Arthur Pharma

Company Introduction

 Arthur Pharmaceutical Co., Ltd.,isfounded in March, 2020. An established pharmaceutical company focusing on complex generic drug development and production. Our newly established injection facility comply with FDA cGMP and China GMP requirements. Currently, more than 30 products are under development. 

Arthur Group LLC, our subsidiary company, is located in New Jersey, with its main business on regulatory filing and US Market distribution.  

 Stage I  :  Arthur Pharma covers an area of 5600m² for its R&D center, which include four teams, the API department, OSD formulation department, Injection formulation department, and R&D department. OurR&D team are located in Jiaxing,Zhejiang,China.

Stage II:  Arthur Pharma is currently establishing an injectablefacility with an area of 33,000 m². It is planned for the production of different injection products, including the oncology products, pre-fill syringe products, and ordinary injection products. Our oral solid productmanufacturinglines are on designing stage. 

Company Introduction

Company Introduction

Company Introduction

   Praxgenis a specialty pharmaceutical company (subsidiary of Arthur Groups) focused on the development, manufacturing and marketing of high-quality generic prescription pharmaceuticals that improve patient health while creating stakeholder value. We specialize in difficult-to-manufacture and complex dosage forms, including ophthalmics, injectables, topicals and oral solids.

We have Research and Development facilities in Princeton, NJ and Monmouth Junction, NJ, and several manufacturing facilities across North America and Asia through partnerships and contract manufacturing.

  Joint Product Development 

Praxgenis seeking partners for joint product development for U.S. and international markets. 

ANDA, 505(b)(2) & NDA

Dr. Isaac Liu

Company Introduction

Dr. Zhang Wei CSO

     PhD in Biophysics and Biochemistry, Stanford University Founder and CEO of Shangjin Pharmaceutical 

Pfizer Pharmaceuticals

 Senior Vice President, Global Strategic Planning and M&A President, Global Contract Machining, Asia Pacific 

Ingredient Department Asia Pacific President

President, Novartis Pharmaceuticals (Asia Pacific) 

Senior Business Management consultant of McKinsey 

Dr. Zhang Wei CSO

Company Introduction

Dr. Zhang Wei CSO

Nearly 30 years of experience in R&D analysis, quality assurance and quality control

Zhejiang University Bachelor, Master New York University Ph.D., Postdoctoral Fellow

Senior Director of Analysis, SUNGENPharmaceuticals, USA

Director of Analysis, Teva Pharmaceutical Industries Ltd. Israel

Barr Laboratories Ltd Analytical Director

Beijing Institute of Technology (China) Associate Professor

Dr. Yang Shicheng CTO

Dr. Gopi Inti Vice President, Scientific Operations USA and Asia Sites

Dr. Gopi Inti Vice President, Scientific Operations USA and Asia Sites

More than 30 years experience in solid dosage development

Ph.D., China Pharmaceutical University

Postdoctoral fellow at Purdue University

Senior Director of Pharmaceutical R&D, Shionogi Pharmaceuticals, Japan

Senior Director of Product Development and Technology Transfer, 

Salus Corporation, USA

Pfizer (China) R&D Manager

Medical Advanced Research

Senior Formulation Researcher,

KV Pharmaceuticals, USA

Dr. Gopi Inti Vice President, Scientific Operations USA and Asia Sites

Dr. Gopi Inti Vice President, Scientific Operations USA and Asia Sites

Dr. Gopi Inti Vice President, Scientific Operations USA and Asia Sites

Dr. Gopi has over 22 years of pharmaceutical research experience with regulatory expertise, having worked with top tier firms including Dr.Reddy's, Mylan CIPLA, InvaGen & Ascent.

He has an extensive background in current FDA regulations and is skilled in cGMP regulated environments.

At Praxgen, He is a part of the executive leadership, plays an integral role in optimizing the R&D portfolio/pipeline strategy and supporting the commercial sales team and general management of 

USA and Asia sites.

In the News

SunGen Pharma Rebrands as Praxgen Pharmaceuticals

Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)

Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)

We are excited to announce that SunGen Pharma has rebranded as Praxgen Pharmaceuticals! 

 Over the past five years, SunGen focused on actively building a company that can both develop a wide range of drug products while maintaining flexibility and dedication to R&D fundamentals.  SunGen is not and has never been affiliated with SUN PHARMA® and/or Sun Pharmaceutical Industries, Ltd. 

Our new name, Praxgen Pharmaceuticals, reflects our commitment to patient health. The path to health should be practical and accessible to everyone, and we aim to help achieve that through high-quality generic pharmaceuticals. 

Amidst this thrilling name change, Praxgen’s quality remains constant. We will continue to focus on developing exemplary prescription drugs for introduction into the market to bring accessibility to the masses. 

Find out more

Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)

Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)

Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)

Oakrum and SunGen announced the U.S. launch and commercial shipment of a generic version of Medrol® (Methylprednisolone) in 4 mg tablets. It is anticipated that the product will serve the retail market with annual sales in the U.S. exceeding $110 million in the aggregate for the 12-month period ending December 31, 2018 according to available data from IQVIA. 

Find out more

SunGen Pharma Receives Seventh ANDA Approval from US FDA

Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)

SunGen Pharma Receives Seventh ANDA Approval from US FDA

The seventh approved ANDA is for Fosaprepitant for Injection 150mg/vial. This drug product is used for treatment of cyclic vomiting syndrome and late-stage, chemotherapy-induced vomiting. This is a sub-blockbuster product of over $350M US market size for 2018 according to IQVIA. Emend®’s patent expired on Sep 4th and SunGen obtained its ANDA approval on Sep 5th, which includes it in the first wave of all generic approvals for Emend®. 

Find out more

Contact Us

Send Message

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Get In Touch

Please reach out to us with any business inquiries.

Praxgen PHARMACEUTICALS

9 Deerpark Dr, Suite J-10, Monmouth Junction, New Jersey 08852, United States

Hours

Monday - Friday: 9am - 5pm

Saturday - Sunday: Closed

Copyright © 2023 Praxgen PHARMACEUTICALS - All Rights Reserved.

Welcome to Praxgen Pharmaceuticals, formerly SunGen Pharma!

Due to COVID-19, we have limited on-site staff. Hours may vary.